Wednesday, May 16, 2012

How much will J&J end up paying for Risperdal?

Pennsylvania still trying get a slice of J&J Risperdal payouts

An appeal being heard today on a case seen as the precursor to the mountains of litigation over Johnson & Johnson's ($JNJ) Risperdal may decide whether Pennsylvania will see any of the millions of dollars other states are now putting into their lean coffers.

Like the others, it alleges that J&J's Janssen Pharmaceuticals, which makes the drug for schizophrenia and bipolar disorder, oversold the drug's benefits while underselling the risks, and all the while reaping billions of dollars in sales. The effort to pump up sales of Risperdal has in fact become the poster child for overzealous drug marketing in the U.S.

No comments: